Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide an opportunity for patients who exhibit progressive
disease while receiving placebo on the companion 93-04-11 study to receive ONTAK. It is also
designed to determine the effectiveness of ONTAK in Cutaneous T-cell Lymphoma (CTCL) patients
whose tumors do not express CD25.